| pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
|---|
| percutaneous coronary intervention | amlodipine | not classified | versus control or placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Jorgensen (NICOLE), 2001 | amlodipine vs placebo | re-PTCA 0.48 [0.23; 0.99] | | restenosis 0.99 [0.73; 1.33] death 0.50 [0.05; 5.47] AMI 0.72 [0.30; 1.78] CABG 0.78 [0.39; 1.53] |
| Trial | Treatments | Patients | Method |
|---|
| Jorgensen (NICOLE), 2001 | amlodipine (10 mg/day) (n=236) vs. placebo (n=215) | | double blind Sample size: 236/215 Primary endpoint: FU duration: 4months |
|
| percutaneous coronary intervention | diltiazem | not classified | versus control or placebo No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Corcos, 1985 | diltiazem vs control | | | restenosis 0.70 [0.29; 1.68] | | O’Keefe, 1991 | diltiazem vs placebo | | | restenosis 1.01 [0.63; 1.64] | | Unverdorben, 1996 | diltiazem vs placebo | restenosis 0.56 [0.34; 0.91] | | |
| Trial | Treatments | Patients | Method |
|---|
| Corcos, 1985 | diltiazem (90 mg tid) (n=46) vs. (n=46) | | open Sample size: 46/46 Primary endpoint: FU duration: 3 months | | O’Keefe, 1991 | diltiazem (240-360 mg/day) (n=61) vs. placebo (n=59) | | double blind Sample size: 61/59 Primary endpoint: FU duration: 12 months | | Unverdorben, 1996 | diltiazem (180 mg/day) (n=84) vs. placebo (n=86) | | double blind Sample size: 84/86 Primary endpoint: FU duration: 4 months |
|
| percutaneous coronary intervention | nifedipine | not classified | versus control or placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Whitworth, 1986 | nifedipine vs placebo | | | restenosis 0.95 [0.61; 1.47] |
| Trial | Treatments | Patients | Method |
|---|
| Whitworth, 1986 | nifedipine (10 mg qid) (n=100) vs. placebo (n=98) | | double blind Sample size: 100/98 Primary endpoint: FU duration: 6 months |
|
| percutaneous coronary intervention | nisoldipine | not classified | versus control or placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Dens (CAPARES), 2000 | nisoldipine vs placebo | CABG 0.08 [0.01; 0.64] | | restenosis 0.89 [0.77; 1.03] death 2.19 [0.20; 24.09] AMI 0.44 [0.09; 2.25] re-PTCA 0.82 [0.65; 1.03] |
| Trial | Treatments | Patients | Method |
|---|
| Dens (CAPARES), 2000 | nisoldipine (40 mg/day) (n=308) vs. placebo (n=338) | | double blind Sample size: 308/338 Primary endpoint: FU duration: 6 months |
|
| percutaneous coronary intervention | verapamil | not classified | versus control or placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Hoberg, 1994 | verapamil vs placebo | | | restenosis 0.77 [0.59; 1.01] |
| Trial | Treatments | Patients | Method |
|---|
| Hoberg, 1994 | verapamil (240 mg bid) (n=89) vs. placebo (n=83) | | double blind Sample size: 89/83 Primary endpoint: FU duration: 6 months |
|
